Open AccessDrug Safety Monitoring Information
Author(s) -
Редакционная статья
Publication year - 2020
Publication title -
bezopasnostʹ i risk farmakoterapii
Language(s) - English
Resource type - Journals
eISSN - 2619-1164
pISSN - 2312-7821
DOI - 10.30895/2312-7821-2020-8-2-104-106
Subject(s) - famotidine , ranitidine , pantoprazole , ondansetron , medicine , drug , business , domperidone , pharmacovigilance , medical emergency , pharmacology , alternative medicine , omeprazole , pathology , dopamine , endocrinology
Experts of the Department for Evaluation of Medicinal Products’ Safety of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of foreign regulatory authorities on the recall of medicines and/or the need to amend the prescribing information due to changes in their safety profile. The analysis helped to identify 11 administrative decisions that contain information on the following medicines registered in Russia: ranitidine, nizatidine, famotidine, pantoprazole, ondansetron, domperidone.